Global Recombinant Human Follicle-stimulating Hormone Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Follicle-stimulating Hormone Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Recombinant Human Follicle-stimulating Hormone report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Follicle-stimulating Hormone market is projected to reach US$ 1523 million in 2034, increasing from US$ 1045.6 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2034. Demand from Infertility Treatment and Assisted Reproductive Technology are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Human Follicle-stimulating Hormone industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Human Follicle-stimulating Hormone key companies include Merck, Ferring, Livzon, Gedeon Richter, GenSci, Teva, ChangChun High & New Technology, ABL and Scripps Laboratories, etc. Merck, Ferring, Livzon are top 3 players and held % share in total in 2022.
Recombinant Human Follicle-stimulating Hormone can be divided into 75IU, 150IU and Others,, etc. 75IU is the mainstream product in the market, accounting for % share globally in 2022.
Recombinant Human Follicle-stimulating Hormone is widely used in various fields, such as Infertility Treatment and Assisted Reproductive Technology, etc. Infertility Treatment provides greatest supports to the Recombinant Human Follicle-stimulating Hormone industry development. In 2022, global % share of Recombinant Human Follicle-stimulating Hormone went into Infertility Treatment filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Follicle-stimulating Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
Segment by Type
75IU
150IU
Others
Infertility Treatment
Assisted Reproductive Technology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Follicle-stimulating Hormone market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Recombinant Human Follicle-stimulating Hormone introduction, etc. Recombinant Human Follicle-stimulating Hormone Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Recombinant Human Follicle-stimulating Hormone market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for Recombinant Human Follicle-stimulating Hormone industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Human Follicle-stimulating Hormone key companies include Merck, Ferring, Livzon, Gedeon Richter, GenSci, Teva, ChangChun High & New Technology, ABL and Scripps Laboratories, etc. Merck, Ferring, Livzon are top 3 players and held % share in total in 2022.
Recombinant Human Follicle-stimulating Hormone can be divided into 75IU, 150IU and Others,, etc. 75IU is the mainstream product in the market, accounting for % share globally in 2022.
Recombinant Human Follicle-stimulating Hormone is widely used in various fields, such as Infertility Treatment and Assisted Reproductive Technology, etc. Infertility Treatment provides greatest supports to the Recombinant Human Follicle-stimulating Hormone industry development. In 2022, global % share of Recombinant Human Follicle-stimulating Hormone went into Infertility Treatment filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Follicle-stimulating Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
Segment by Type
75IU
150IU
Others
Segment by Application
Infertility Treatment
Assisted Reproductive Technology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Follicle-stimulating Hormone market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Recombinant Human Follicle-stimulating Hormone introduction, etc. Recombinant Human Follicle-stimulating Hormone Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Recombinant Human Follicle-stimulating Hormone market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices